NFE2L2 and hepatocellular carcinoma: To determine the inducer potency of PRL-295, we used a quantitative bioassay in murine hepatoma (Hepa1c1c7) cells, which measures the enzyme activity of the classical Nrf2 target, NAD(P)H:quinone oxidoreductase 1 (NQO1) as the readout (Fahey et al., 2004).